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Materials and Methods
Animals. C57BL/6 (B6), 1 BALB/c, A/J, DBA/1, and CBAdHT6 (CT6) mice, 8-10 wk of age, were obtained from The Jackson Laboratory, Bar Harbor, Maine. CBA/N mice were originally obtained from the NIH and maintained at Yale by R. K. Gershon. CBA/N ~ mice were mated with BALB/c dto produce normal F1 Q and defective F1 ~hybrid offspring.
Preparation of Lymphocyte Subpopulations. Whole spleen cell suspensions were prepared by teasing the spleen with forceps in a Petri dish containing phosphate-buffered saline plus 5% fetal calf serum and then flushing the suspension through a nylon gauze. Macrophage-depleted spleen cells were prepared by incubating spleen cells with carbonyl-iron on a rotator at 37°C for 1/2 h; the cells were then settled on a magnet and the supernatant cells removed. Purified T lymphocytes were obtained from nylon wool columns, according to the method used by Julius et al. (13) ; 80-90% of the recovered cells were Thyl + and 5-10% were Ig +. Non-T cells were obtained by treating spleen cells twice with anti-Thyl plus complement (C). Highly purified B cells were also obtained by elution of spleen cells from a Rabbit anti(a)-mouse-Fab coated Sephadex G-200 column (14) ; these cells were 96-99% Ig + by immunofluorescent criteria.
Analysis of Binding Activity ofSera. 2 .5 x 106 lymphocytes were incubated with 50 ftl of test or control sera at various dilutions for 1/2 h at 4°C in the presence of 0.2% Na azide. After washing three times, the cells were then incubated with a fluorescein-conjugated goat a-mouse mIgG (GaMIgG) kindly provided by Dr. L. A. Herzenberg, Stanford Medical School, Stanford, Calif. Background levels of spleen cell fluorescence, as indicated by the numbers of fluorescent cells treated with control serum, followed by fluorescein isothiocyanate (FITC) GaMIgG, were less than 3%. All sera were ultracentrifuged at 40,000 rpm for 20 min to remove aggregated material.
Analysis of Functional Activity of Test and Control Sera. Mice were immunized intravenously
(i.v.) with sheep erythrocytes (SRBC) or horse erythrocytes (HRBC) alone or in combination with varying dilutions of test or control serum; 4-8 days later the mice were killed and the number of spleen plaque-forming cells (PFC) to sRBC or HRBC was determined in a modified Cunningham assay (15) . In some experiments, '<B" mice, i.e. thymectomized, lethally irradiated mice restored with T-cell-deficient bone marrow (for details see reference 15), were immunized with SRBC and test or control sera. tions was performed at 4°C for 1 h at a concentration of 50-100 x 106 cells/40 ~l serum.
Results
I. Production of
H. Analysis of Reactivity of the Test and Control Sera
(a) DOSE RESPONSE OF ANTISERA (FIG. 1) . No cytotoxicity was apparent after spleen cells from BALB/c mice were exposed to different concentrations of the test antiserum in the presence of a highly active rabbit C. To determine whether the serum specifically reacted with BALB/c cells but did not fix C, spleen cells were incubated with varying dilutions of test or control serum and then labeled with FITC-GaMIgG (which reacts directly with <2% of B cells). This approach demonstrated that the test serum reacted with approximately 20-30% of the spleen cells in dilutions as high as 1:40, compared with control serum which was completely unreactive. Therefore, in the following experiments, the test and control sera were used at a final dilution of 1:20. (c) ONTOGENY OF Lyb3 CELLS (TABLE I B) . Reactivity of the ~Lyb3 serum against spleen cells from B6 mice of different ages was determined. No reactivity was noted against cells from newborn mice; at 18 days 19% of the cells were Lyb3 + while maximum reactivity (30%) was noted using spleen cells from mice 110 days of age. (TABLE IC) . We compared the proportion of Lyb3 + spleen cells obtained from B6, BALB/c, CT6, DBA/1, and A/J and CBA/N mice. B6 and BALB/c spleen populations contained 30% Lyb3 ÷ cells; CT6, DBA/1, and A/J mice about 25%; and CBA/N 0-5%. The reactivity of ~Lyb3 against spleen cells from CBA/N mice (5%) was reduced to undetectable levels by preincubating the cells with aggregated normal mouse serum to block Fc receptor binding; such pretreatment had no influence on the reactivity of aLyb3 serum with spleen cells from other strains. produced 15 to 20-fold more anti-SRBC PFC (Fig. 2) . Injection of higher doses of antiserum resulted in progressively decreasing responses, probably reflecting either an opsonization effect or the presence of excessive amounts of aLyb3 on the surface of B cells. Similar enhancement of aSRBC responses of CT6 and B6 mice were also observed. In contrast, i.v. injections of varying doses of aLyb3 serum failed to enhance the anti-SRBC PFC response of CBA/N mice, indicating that the enhancement effect was clearly due to a specific reaction of the serum with a component which is absent in the CBA/N mice (Fig. 3) . Finally, studies of the time-course of this enhanced PFC response also indicated that the peak response occurred on day 6, and by day 8 the response had declined to normal levels ( Fig. 3) .
III. Ability of oLLyb3 Serum to Trigger B Cells to Produce Specific Antibody after In Vivo Immunization with Low Doses of Antigen
(b) ~Lyb3 ENHANCEMENT IS ANTIGEN SPECIFIC (TABLE II) . Mice injected with aLyb3 serum without antigen did not produce significant PFC responses to either SRBC or HRBC. In addition, the enhanced PFC response of mice immunized with low doses of either SRBC or HRBC plus ~Lyb3 was specific for the immunogen. These findings indicate that aLyb3 serum acts synergistically with antigen to produce enhanced antigen-specific PFC responses. direct interaction between aLyb3 and a component on the surface of B cells.
Analysis of the Role of Lyb3 in Antigen-Dependent B-Cell Triggering.
The data presented in section IH suggest that stimulation of the Lyb3 surface component on antigen-reactive B cells allows more efficient triggering of these cells by antigen. This implies that the CBAJN mouse, which lacks Lyb3 + B cells, might be expected to respond poorly to relatively low doses of antigen. We therefore compared the PFC responses of CBAJN mice and CT6 age-and sex-matched mice (the latter are identical to the CBA/N as judged by indefinite mutual acceptance of skin grafts, B. Huber, unpublished observation). CBA/N mice were unable to produce significant PFC responses to relatively low doses of antigen, in contrast to CT6 (Fig. 4 A) .
To test the notion that the enhancing effects of aLyb3 serum upon the PFC response of the normal strain (CT6) would be particularly decisive when the signal provided by antigen and T cells is relatively low, we examined the enhancing effects of aLyb3 in the presence of (a) different concentrations of antigen and (b) in the presence of limiting numbers of T cells. The administration of aLyb3 serum markedly enhanced the reponse of CT6 mice to low doses of SRBC (Fig. 4 B) . By contrast, the response of these mice to large doses of SRBC was not significantly enhanced by the administration of aLyb3 serum. These findings are consistent with the idea that increased eft]- ciency of the antibody response in the presence of aLyb3 serum is most apparent when the antigen-induced signal is suboptimal. The ability of aLyb3 to substitute for T-helper activity in the induction of a primary and secondary response was also tested. B mice (see Materials and Methods) did not produce significant aSRBC after priming with up to 10 s SRBC plus control serum; the administration of aLyb3 to these mice resulted in the production of a significant PFC response (Table IV A) .
Moreover, B cells from antigen-primed donors could adoptively transfer a secondary antibody response to lethally irradiated hosts only if co-transferred with Lyb3 plus antigen (Table IV B) . No response was seen if the primed B cells were transferred with antigen alone or with aLyb3 alone.
Discussion
The studies of Scher and his co-workers have indicated a B-cell maturation defect in CBA/N mice (see introduction). Our work confirms and extends these findings. We have shown that serum produced by immunization of defective F~ mice with nondefective parental cells reacts predominantly with a subclass of B cells from mice of many H-2 genotypes. Although a possible additional reaction with macrophages has not been ruled out, the serum does not react with thymocytes or T cells (and cannot be absorbed by brain cells, liver cells, or kidney cells, data not shown). Since this antiserum, provisionally termed aLyb3, does not react with BM cells and reacts only weakly with splenic B cells from young mice, it is likely that it defines a cell surface differentiation component(s) expressed selectively on mature B cells.
In view of Lyb3 expression on the surface of B cells from all mouse strains tested, it is likely that this component is specified by genes expressed during the differentiation of B cells of all mouse strains. The present studies do not indicate the location of the structural gene(s) coding for this component and, since it is likely that the present method of immunization has defined a constant portion of this structure, these data do not bear upon whether Lyb3 is expressed as different alleles in different mouse strains.
The reaction of aLyb3 with B cells from all strains tested (except CBA/N) markedly enhanced the development of antigen-specific PFC in the presence of suboptimal doses of antigen. This enhancement reflected a direct interaction between Lyb3 antiserum and a component on the surface of B cells, since enhancing activity was removed by absorption of the serum with B cells, but not T cells, thymocytes, or BM cells. Enhancement is very likely due to stimulation of Lyb3 + B cells, rather than removal of"suppressive" B cells by opsonization, in view of (a) the loss of enhancement with increasing doses of aLyb3 and (b) the finding that similar enhancing effects can be produced in vitro (data not shown).
Since, (a) Lyb3 antiserum does not induce a '~polyclonal" PFC response when administered without antigen, and (b) the enhancement of antibody produced is specific for the immunizing antigen, it is likely that it interacts with a B-cell surface structure that is directly involved in antigen-dependent B-cell triggering. Possibly this surface component(s) normally acts to increase the efficiency of specific B-cell triggering by antigen and/or T-cell factors. This possibility is illustrated most directly by the finding that the CBA/N mutant, lacking Lyb3 + B cells, fails to respond to doses of antigen that elicit substantial responses in the nonmutant CBA/HT6 strain.
Lyb3 may represent the ~'constant portion" of the B-cell antigen receptor or may be distinct from the Ig antigen receptor. Since, (a) the administration of aLyb3 serum can partially replace the requirement for T cells in both primary and secondary responses to a thymus-dependent antigen (see Results, section IV), (b) CBA/N mice do not generate normal profiles of T-cell-dependent high affinity antibodies after immunization with SRBC (11), and (c) the aLyb3 serum described here has no anti-T-cell activity (see Results, sections IIb and HI c), it is possible that this serum reacts with a previously undefined cell surface component(s) on a subclass of B cells which acts as a receptor for a certain T-cell signal(s). This signal would result in more efficient triggering of a portion of B cells by antigen, as well as the subsequent generation of high affinity antibody.
The idea that a special subclass of mature B cells is required for the PFC response to low concentrations of antigen and for the production of high affinity antibody is most clearly suggested from the work of Goidl and Siskind (17) . These authors showed that, in the presence of identical numbers of adult T cells and in the same adult environment, splenic B cells from mice less than 7 days of age do not produce high affinity antibody, whereas B cells from older mice (i.e., greater than 10 days of age) do. Their work suggests that between 1 and 2 wk of age B cells undergo a maturational event which may allow a portion of B cells to B cells of CBA/N mice also do not respond normally to certain ~'thymusindependent" antigens (e.g., trinitrophenyl(TNP)-Ficoll) but do respond to others (e.g., TNP-lipopelysaccharide). The present studies do not directly indicate whether cells of the Lyb3 ÷ subclass are responsible for reactivity to the TNPFicoll category of thymus-independent antigens. Possibly the defective response of CBA/N mice to this category of antigens may reflect an arrest of normal B-cell maturation, resulting in an absence of a mature Lyb3 + B-cell subclass which can respond without T-cell help to certain thymus-independent antigens.
Taken together, these considerations suggest that aLyb3 serum may prove extremely useful in understanding the molecular basis of B-cell triggering. In addition, some practical implications of aLyb3 activity deserve comment. Injections of relatively small quantities of this serum along with weakly immunogenic doses of antigen result in a substantial (10-to 20-fold) increase in specific antibody formation. It is therefore possible that aLyb3 serum will prove useful as a potent stimulus of specific antibody production against relatively weak antigens such as Ig idiotypes, minor histocompatibility products, tumor-associated determinants, and cell surface differentiation antigens. Since the enhanced plaque-forming cell (PFC) responses are specific for the immunizing antigen, and since no PFC response is produced by injection of the antiserum alone, this enhancement probably reflects a second signal produced by specific interaction between antibody and the surface Lyb3 component. Moreover, this signal can partially replace the requirement for T cells in the production of antibody to a "thymus-dependent" antigen. These findings (taken in conjunction with the previously described immune defects in CBA/N mice and other studies of B-cell maturation) suggest to us that Lyb3 is a cell surface component expressed selectively on a mature B-cell subclass. This component is important in B-cell triggering by antigen and fails to develop in CBA/N mice, due to a dysfunction of a regulatory gene on the CBA/N X chromosome.
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